Form 4: Merus Director Cashes Out Options in Genmab Tender Offer

Merus N.V. director Maxine Gowen's share options were cancelled for cash following Genmab's successful tender offer at $97.00 per share.

Summary

• Merus N.V. director Maxine Gowen's share options were cancelled for cash on December 12, 2025, as a result of a tender offer by Genmab A/S.
• Genmab, through its subsidiary Genmab Holding II B.V., acquired all issued and outstanding common shares of Merus N.V. for a cash payment of $97.00 per share.
• The options were cancelled in exchange for a cash payment equal to the difference between the $97.00 Offer Consideration and the option's exercise price, multiplied by the number of shares underlying the option.
• A total of 73,252 share options with various exercise prices ranging from $13.06 to $48.73 were cancelled.

Sentiment

Score: 7

Explanation: The successful completion of the tender offer at a premium price is a positive outcome for Merus N.V. shareholders and option holders, including the reporting person, as it provides a clear cash exit. While it marks the end of Merus as an independent entity, the financial terms are favorable.

Positives

• Maxine Gowen received a cash payment for her in-the-money share options, providing a clear financial benefit.
• The successful completion of the tender offer at $97.00 per share provided a premium cash exit for Merus N.V. shareholders.

Negatives

• The cancellation of options means Maxine Gowen will not participate in any potential future upside of Merus N.V. as an independent entity.
• Merus N.V. will cease to be an independent publicly traded company following the acquisition.

Future Outlook

NA

Industry Context

This announcement reflects the finalization of an acquisition in the biotechnology sector, where a larger entity (Genmab) has acquired a smaller, publicly traded company (Merus N.V.) through a tender offer. Such transactions are common for strategic consolidation or to gain access to specific pipelines or technologies.

Stakeholder Impact

• Shareholders who tendered their shares received $97.00 per share in cash.
• Option holders, including director Maxine Gowen, received cash for their in-the-money options, effectively monetizing their equity incentives.
• Employees holding similar options would also be impacted by the cash-out.

Next Steps

• Cash payment for the tendered shares and cancelled options will be made as soon as practicable following the Acceptance Time.

Key Dates

Keywords

Merus N.V., MRUS, Genmab, Tender Offer, Acquisition, Share Options, Form 4, Insider Transaction, Maxine Gowen